Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
13,512
Total Claims
$1.4M
Drug Cost
814
Beneficiaries
$1,722
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-73%
Opioid rate vs peers
0.6% vs 2.2% avg
+22%
Cost per patient vs peers
$1,722 vs $1,411 avg
+3%
Brand preference vs peers
11.0% vs 10.6% avg
Opioid Prescribing
0.6%
Opioid Rate
82
Opioid Claims
$3,220
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,465 claims · $1.1M
Generic: 11,911 claims · $276K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 166 | $203K |
| Insulin Glargine,hum.Rec.Anlog | 118 | $121K |
| Valbenazine Tosylate | 12 | $103K |
| Semaglutide | 65 | $97K |
| Fluticasone/Umeclidin/Vilanter | 64 | $76K |
| Sitagliptin Phosphate | 57 | $74K |
| Empagliflozin | 37 | $46K |
| Insulin Glargine,hum.Rec.Anlog | 27 | $38K |
| Rivaroxaban | 23 | $35K |
| Dapagliflozin Propanediol | 20 | $34K |
| Insulin Detemir | 25 | $25K |
| Fluticasone/Vilanterol | 26 | $20K |
| Liraglutide | 11 | $17K |
| Insulin Lispro | 14 | $15K |
| Mirabegron | 11 | $15K |
Prescribing Profile
Patient Profile
76
Avg Age
52%
Female
1.34
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data